Previous close | 26.40 |
Open | 31.25 |
Bid | 27.50 |
Ask | 29.70 |
Strike | 190.00 |
Expiry date | 2024-05-17 |
Day's range | 26.40 - 31.25 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.